Metastatic Bladder Cancer Archives - Grand Rounds in Urology

Immune Checkpoint Inhibitors

by Daniel P. Petrylak, MD | Jan 2023

Daniel P. Petrylak, MD, explores immune checkpoint inhibitors for the management of bladder cancer, especially metastatic urothelial carcinoma.

Bladder Cancer Journal Vol. 8, Issue 1

by Bladder Cancer Journal | Mar 2022

Sensitivity and Specificity in Urine Bladder Cancer Markers – Is it that Simple? Abstract: Marker...

Bladder Cancer Journal Vol. 7, Issue 4

by Bladder Cancer Journal | Jan 2022

The Pros and Cons of “Machination of Medicine” in Genitourinary Practice ABSTRACT: The...

Bladder Cancer Journal Vol. 7, Issue 3

by Bladder Cancer Journal | Sep 2021

Muscle-Invasive Bladder Cancer in Patients with Liver Cirrhosis: A Review of Pertinent...

Bladder Cancer Journal Vol. 7, Issue 2

by Bladder Cancer Journal | Jun 2021

Rationale for Randomized Clinical Trials Investigating the Potential of BCG Vaccination in...

Bladder Cancer Journal Vol. 7, Issue 1

by Bladder Cancer Journal | Apr 2021

Tumor Subtyping: Making Sense of Heterogeneity with a Goal Toward Treatment ABSTRACT: BACKGROUND:...

Bladder Cancer Journal Vol. 6, Issue 4

by Bladder Cancer Journal | Dec 2020

Upregulated FGFR3 signaling in NMIBC and MIBC, the diagnosis and management of checkpoint inhibitor side effects in bladder cancer patients, the etiology of treatment delays in patients receiving neoadjuvant chemotherapy for MIBC, and 25-year trends in stage-specific incidence rates for bladder cancer.